134 related articles for article (PubMed ID: 14534743)
1. Autologous soluble tumor-associated antigens prevent the toxic side effects of cancer chemotherapy and inhibit the progress of tumorigenesis: case report.
Ben-Hur H; Zusman R; Zusman I
Oncol Rep; 2003; 10(6):2059-61. PubMed ID: 14534743
[TBL] [Abstract][Full Text] [Related]
2. Rat soluble tumor-associated antigens inhibit chemically-induced mammary tumorigenesis in syngeneic rats.
Kossoy G; Ben-Hur H; Elhayany A; Schneider DF; Zusman I
Oncol Rep; 2005 Apr; 13(4):585-8. PubMed ID: 15756427
[TBL] [Abstract][Full Text] [Related]
3. Human soluble tumor-associated antigens promote the suppression of rat mammary tumors by 5-fluorouracil and stimulate the functional activity of immune organs: Experimental and morphological studies.
Kossoy G; Ben-Hur H; Avinoach I; Alhayany A; Shneider DF; Zusman I
Int J Mol Med; 2003 Nov; 12(5):797-801. PubMed ID: 14533012
[TBL] [Abstract][Full Text] [Related]
4. Effects of cyclophosphamide and soluble tumor-associated antigens on lymphoid infiltration, proliferative activity and rate of apoptosis in chemically-induced rat mammary tumors.
Ben-Hur H; Kossoy G; Tendler Y; Kossoy N; Zusman I
In Vivo; 2002; 16(5):287-92. PubMed ID: 12494865
[TBL] [Abstract][Full Text] [Related]
5. Human soluble p66 and p51 tumor-associated antigens promote the suppression of rat mammary tumors in comparison to commercial human albumin.
Kossoy G; Avinoach I; Zusman I; Scheider DP; Ben-Hur H; Elhayany A
Oncol Rep; 2004 Feb; 11(2):487-91. PubMed ID: 14719088
[TBL] [Abstract][Full Text] [Related]
6. Soluble low-molecular-mass tumor-associated antigens promote the suppression of rat mammary tumors by tamoxifen and prevent its toxic effect.
Ben-Hur H; Kossoy G; Zusman I
Int J Oncol; 2002 Feb; 20(2):413-7. PubMed ID: 11788910
[TBL] [Abstract][Full Text] [Related]
7. Cytological aspects of rat mammary cancer therapy with soluble tumor-associated antigens and anticancer drugs.
Zusman I
Med Sci Monit; 2005 May; 11(5):RA173-181. PubMed ID: 15874908
[TBL] [Abstract][Full Text] [Related]
8. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.
Schulze T; Kemmner W; Weitz J; Wernecke KD; Schirrmacher V; Schlag PM
Cancer Immunol Immunother; 2009 Jan; 58(1):61-9. PubMed ID: 18488223
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
[TBL] [Abstract][Full Text] [Related]
11. Response of T- and B-lymphocytes in the spleen of mammary tumor-bearing rats to treatment with tamoxifen and soluble tumor-associated antigens.
Ben-Hur H; Kossoy G; Sanko H; Geva D; Shumlin N; Zusman I; Elhayany A
Oncol Rep; 2004 Jul; 12(1):181-5. PubMed ID: 15201981
[TBL] [Abstract][Full Text] [Related]
12. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas.
Tanaka F; Haraguchi N; Isikawa K; Inoue H; Mori M
Oncol Rep; 2008 Nov; 20(5):1111-6. PubMed ID: 18949409
[TBL] [Abstract][Full Text] [Related]
13. Response of T and B lymphocytes in the spleen, lymph nodes and mammary tumors in rats treated with human soluble tumor-associated antigens and commercial human albumin.
Ben-Hur H; Kossoy G; Mehrdad H; Elhayany A; Zusman I
Oncol Rep; 2004 Dec; 12(6):1329-33. PubMed ID: 15547759
[TBL] [Abstract][Full Text] [Related]
14. T cell kinetics and apoptosis in immune organs and mammary tumors of rats treated with cyclophosphamide and soluble tumor-associated antigens.
Zusman I; Kossoy G; Ben-Hur H
In Vivo; 2002; 16(6):567-76. PubMed ID: 12494902
[TBL] [Abstract][Full Text] [Related]
15. Preventive effect of the soluble tumor-associated antigens on DMBA induced tumorigenesis in C3H/He mice.
Kossoy G; Ben-Hur H; Elhayany A; Schneider DF; Kossoy N; Zusman I
Oncol Rep; 2005 Dec; 14(6):1625-9. PubMed ID: 16273267
[TBL] [Abstract][Full Text] [Related]
16. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.
Haanen JB; Baars A; Gomez R; Weder P; Smits M; de Gruijl TD; von Blomberg BM; Bloemena E; Scheper RJ; van Ham SM; Pinedo HM; van den Eertwegh AJ
Cancer Immunol Immunother; 2006 Apr; 55(4):451-8. PubMed ID: 16034562
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
20. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
